In order to better improve the performance ability, management level, innovative thinking and work execution of middle managers, and strive to build a high-quality cadre team, the three-period training was successfully concluded, and 11 middle managers participated in the training.
From leadership to execution, the three-stage training adopts a variety of teaching methods such as combining theoretical teaching and case study, classroom teaching and practical work, covering production organization, self-management, team building, action learning and other aspects, achieving systematic, targeted and practical organic unity. During the training process, the students listened carefully, actively discussed, and completed the learning task with a positive attitude, full of spirit and rigorous style of study.
The participants agreed that participating in this training increased knowledge, broadened their horizons, broadened their ideas, further improved their theoretical literacy, further stimulated their enterprising consciousness, further strengthened their comprehensive ability, and strengthened their entrepreneurial confidence. Everyone said that we should take this training as a new starting point, continue to learn, apply what we learn, and strive to convert the learning results into ideas for planning work, measures for implementing work, and the ability to do a good job, based on the long-term development of a startup company.
Kang Yu Xin biological
Kangyuxin Biotechnology Co., Ltd. was established in October 2013, specializing in the research and development, production, sales and related service technology development of pyrazine intermediates and process libraries. Kangyuxin has more than 2,000 square meters of standardized laboratories, with an output value of more than 80 million yuan in 2022. The core technology of pyrazine derivatives of Kangyuxin ranks the leading level in China, and the varieties and orders of pyrazine series products are ranked first in the domestic industry. Kangyuxin has an experienced and high-quality drug process research and development team, which can realize the research and development and process production from lead compounds to clinical batch apis. Kangyuxin Drug Quality research team can provide effective data and method validation for drug registration and research.
The company was supported by the innovation Fund of Gansu Province in 2016, and was identified as the first batch of provincial science and technology innovation enterprises by the Department of Science and Technology of Gansu Province, and has been supported by the science and technology innovation Fund of Lanzhou and Baiyin for many times. Wang Youwei, the founder of the company, was named "One hundred innovative and entrepreneurial models in Lanzhou City" in 2015. Kangyuxin, as the first enterprise to develop a broad spectrum antiviral new drug "Fabilavir" in China, was shortlisted for the eighth batch of epidemic prevention materials in Gansu Province, Kangyuxin won the excellence Award of the 10th China Innovation and Entrepreneurship Competition National biomedical Industry Competition in 2021 (the second place in the group), and the second place in the Gansu Division of the 10th China Innovation and Entrepreneurship Competition. Won the first prize in the Northwest region of the 2020 "Guotong Cup" Lanzhou University Global Alumni Entrepreneurship Competition, and the first prize of the Baiyin Double Innovation Competition for two consecutive years in 2020 and 2021. In 2022, it will be evaluated as a high-tech enterprise and a specialized and special new enterprise.
